Intravesical therapy in recurrent cystitis: A multi-center experience

Journal of Infection and Chemotherapy

Volumn 19, Issue 5, 2013, Pages 920-925

  Torella, Marco ^a   Schettino, Maria Teresa ^a   Salvatore, Stefano ^b   Serati, Maurizio ^c   De Franciscis, Pasquale ^a   Colacurci, Nicola ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^c UNIVERSITY OF INSUBRIA   (Italy)

Author keywords

Chondroitin sulfate; Fosfomycin; Hyaluronic acid; Intravesical therapy; Recurrent cystitis

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; CEFUROXIME; CHONDROITIN SULFATE; CIPROFLOXACIN; COTRIMOXAZOLE; FOSFOMYCIN; HYALURONIC ACID; IALURIL 1; NITROFURANTOIN; NORFLOXACIN; TRIMETHOPRIM; UNCLASSIFIED DRUG;

ADULT; ANTIBIOTIC SENSITIVITY; ARTICLE; CYSTITIS; CYSTOSCOPY; DRUG EFFICACY; FOLLOW UP; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; PAIN ASSESSMENT; RECURRENT DISEASE; SEXUAL FUNCTION; TREATMENT RESPONSE; URINALYSIS; URINARY TRACT INFECTION; URINE CULTURE; VISUAL ANALOG SCALE;

ADMINISTRATION, INTRAVESICAL; ANTI-BACTERIAL AGENTS; CHONDROITIN SULFATES; CYSTITIS; FEMALE; FOSFOMYCIN; HUMANS; HYALURONIC ACID; MIDDLE AGED; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; UROLOGICAL AGENTS;

EID: 84885951116     PISSN: 1341321X     EISSN: 14377780     Source Type: Journal    
DOI: 10.1007/s10156-013-0609-6     Document Type: Article

References (29)

1. Salvatore S, Salvatore S, Cattoni E, et al. Urinary tract infections in women. Eur J Obstet Gynecol Reprod Biol. 2011;156:131-6.
2. Ronald A. The etiology of urinary tract infection: traditional and emerging pathogens. Am J Med. 2002;113:14S-9S.
3. Trabucco E, Soderberg M, Cobellis L, et al. Role of proteoglycans in the organization of periurethral connective tissue in women with stress urinary incontinence. Maturitas. 2007;58:395-405.
4. Hannan TJ, Totsika M, Mansfield KJ, et al. Host-pathogen checkpoints and population bottlenecks in persistent and intracellular uropathogenic Escherichia coli bladder infection. FEMS Microbiol Rev. 2012;36:616-48.
5. Soler R, Bruschini H, Martins JR, et al. Urinary glycosaminoglycans as biomarker for urothelial injury: is it possible to discriminate damage from recovery? Urology. 2008;72:937-42.
6. Di Pietto L, Scaffa C, Lambiase A, et al. Perineal ultrasound evaluation of urethral mobility after the TVT-O procedure. Clin Exp Obstet Gynecol. 2010;37:131-4.
7. Di Pietto L, Scaffa C, Torella M, et al. Perineal ultrasound in the study of urethral mobility: proposal of a normal physiological range. Int Urogynecol J Pelvic Floor Dysfunct. 2008;19:1405-9.
8. Palomba S, Oppedisano R, Torella M, The SIMS Italian Group, et al. A randomized controlled trial comparing three vaginal kits of single-incision mini-slings for stress urinary incontinence: surgical data. Eur J Obstet Gynecol Reprod Biol. 2012;163:108-12.
9. Serati M, Ghezzi F, Cattoni E, et al. Tension-free vaginal tape for the treatment of urodynamic stress incontinence: efficacy and adverse effects at 10-year follow-up. Eur Urol. 2012;61:939-46.
10. Serati M, Bauer R, Cornu JN, et al. TVT-O for the treatment of pure urodynamic stress incontinence: efficacy, adverse effects, and prognostic factors at 5-year follow-up. Eur Urol 2012. doi: 10.1016/j.eururo.2012.12.022.
11. Gillenwater JY, Wein AJ. Summary of the National Institute of Arthritis, Diabetes, Digestive and Kidney Diseases workshop on interstitial cystitis. National Institutes of Health, Bethesda, Maryland, August 28-29. J Urol. 1988;140:203-6.
12. Falagas ME, Giannopoulou KP, Kokolakis GN, et al. Fosfomycin: use beyond urinary tract and gastrointestinal infections. Clin Infect Dis. 2008;46:1069-77.
13. Baylan O. Fosfomycin: past, present and future. Mikrobiyol Bul. 2010;44:311-21.
14. Michalopoulos AS, Livaditis IG, Gougoutas V. The revival of fosfomycin. Int J Infect Dis. 2011;15:732-9.
15. Avorn J, Monane M, Gurwitz JH, et al. Reduction of bacteriuria and pyuria after ingestion of cranberry juice. J Am Med Assoc. 1992;271:751-4.
16. Reid G. The scientific basis for probiotic strains of Lactobacillus. Appl Environ Microbiol. 1999;65:3763-6.
17. Shao Y, Shen ZJ, Rui WB, et al. Intravesical instillation of hyaluronic acid prolonged the effect of bladder hydrodistention in patients with severe interstitial cystitis. Urology. 2010;75:547-50.
18. Porru D, Leva F, Parmigiani A, et al. Impact of intravesical hyaluronic acid and chondroitin sulfate on bladder pain syndrome/interstitial cystitis. Int Urogynecol. 2012;23:1193-9.
19. Southgate J, Varley CL, Garthwaite MA, et al. Differentiation potential of urothelium from patients with benign bladder dysfunction. BJU Int. 2007;99:1506-16.
20. Constantinides C, Manousakas T, Nikolopoulos P, et al. Prevention of recurrent bacterial cystitis by intravesical administration of hyaluronic acid: a pilot study. BJU Int. 2004;93:1262-6.
21. Lipovac M, Kurz C, Reithmayr F, et al. Prevention of recurrent bacterial urinary tract infections by intravesical instillation of hyaluronic acid. Int J Gynaecol Obstet. 2007;96:192-5.
22. Damiano R, Quarto G, Bava I, et al. Prevention of recurrent urinary tract infections by intravesical administration of hyaluronic acid and chondroitin sulphate: a placebo-controlled randomised trial. Eur Urol. 2011;59:645-51.
23. De Vita D, Giordano S. Effectiveness of intravesical hyaluronic acid/chondroitin sulfate in recurrent bacterial cystitis: a randomized study. Int Urogynecol J. 2012;23:1707-13.
24. Ronald AR, Harding CK, Mathias R, et al. Prophylaxis of recurring urinary tract infection in females: a comparison of nitrofurantoin with trimethoprim-sulfamethoxazole. Can Med Assoc J. 1975;112:13-6.
25. Kerrn MB, Struve C, Blom J, Frimodt-Møller N, Krogfelt KA. Intracellular persistence of Escherichia coli in urinary bladders from mecillinam-treated mice. J Antimicrob Chemother. 2005;55:383-6.
26. Schmiemann G, Gágyor I, Hummers-Pradier E, Bleidorn J. Resistance profiles of urinary tract infections in general practice: an observational study. BMC Urol. 2012;12:33.
27. Maraki S, Samonis G, Rafailidis PI, Vouloumanou EK, Mavromanolakis E, Falagas ME. Susceptibility of urinary tract bacteria to fosfomycin. Antimicrob Agents Chemother. 2009;53:4508-10.
28. Albert X, Huertas I, Pereiró II, et al. Antibiotics for preventing recurrent urinary tract infection in non-pregnant women. Cochrane Database Syst Rev 2004;CD001209
29. Dason S, Dason JT, Kapoor A. Guidelines for the diagnosis and management of recurrent urinary tract infection in women. Can Urol Assoc J. 2011;5:316-22.